This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrial fibrillation (AF), but its impact on outcomes in real-world practice is uncertain. years) were enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy/Myocarditis Registry. Methods Overall, 1739 adult patients with HCM (40.9%
BackgroundPediatric cardiomyopathies are rare but life-threatening conditions with high mortality. ConclusionsThis study underscores the importance of early diagnosis, genetic testing, and integrated management in pediatric cardiomyopathies. Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed.
Background High-intensity physical activity has traditionally been discouraged in patients with hypertrophic cardiomyopathy due to concerns about triggering sudden cardiac death. However, current guidelines adopt a more liberal stance, and evidence on risk factors for exercise-related sudden cardiac death remains limited.
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. Clinical status was evaluated using New York Heart Association (NYHA) class and Kansas City Cardiomyopathy Questionnaire (KCCQ) score.
Dilated cardiomyopathy (DCM) is a leading cause of heart failure, yet therapeutic options remain limited. In this narrative review, we summarize the key role of MAMs, crucial endoplasmic reticulum (ER)-mitochondria interfaces, in regulating cellular processes such as calcium homeostasis, lipid metabolism, and mitochondrial dynamics.
Getty Images milla1cf Tue, 05/14/2024 - 13:00 May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the walls of the left ventricle to become thick and stiff. The late breaking research was presented by principal investigator Martin S.
Background Little evidence is available about heart rate (HR) response to exercise as well as its relationship with functional capacity in amyloid cardiomyopathy. Methods Data from 172 outpatients with amyloid cardiomyopathy who performed a maximal CPET and who had no significant rhythm disorders were analysed.
In the present study, we report a case initially treated as obstructive hypertrophic cardiomyopathy for several years, which was finally identified as FD through whole-exome sequencing (WES). The patient, diagnosed with obstructive hypertrophic cardiomyopathy, underwent left ventricular outflow tract surgery before visiting our hospital.
(MedPage Today) -- The American West has seen the biggest surge of cardiomyopathy-associated hospital admissions among methamphetamine users, based on 13 years of the latest available hospital admission data. The National Inpatient Sample (NIS.
Childhood-onset cardiomyopathies represent a rare and poorly understood subset of cardiac disorders. In a recent study published in the European Heart Journal, investigators delved into the demographics and prognosis of pediatric cardiomyopathy patients within the inaugural European Cardiomyopathy Registry. months (IQR: 11.3–15.3),
Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype. 4 Indeed, the use of CPET is recognised in HF guidelines 5 and parameters such as peak oxygen consumption (VO 2peak ) offer a.
(MedPage Today) -- A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH), researchers found. From proteomic profiling of nearly.
As of now, there are no data to support its use as a treatment for diabetic cardiomyopathy (DCM) and the mechanism behind the effect is unclear as well. BackgroundZhigancao Decoction (ZGCD) is derived from Treatise on Febrile Diseases and is traditionally prescribed for treating a variety of cardiovascular conditions.
Experts released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). The guideline reiterates the importance of collaborative decision-making with patients who have HCM and provides updated recommendations for the most effective treatment pathways for adult and pediatric patients.
Reversible cardiomyopathy with severe heart failure is a rare complication of adrenal crisis. In summary, we described a rare and severe case of adrenal crisis complicated with reversible cardiomyopathy that was caused by isolated ACTH deficiency.
Diabetic cardiomyopathy (DC) is a serious condition characterized by impaired heart function due to diabetes-related metabolic abnormalities. Diabetes is a global health burden. A whopping 536 million people worldwide struggle with diabetes.
(MedPage Today) -- Updates to national guidelines for the management of hypertrophic cardiomyopathy (HCM) endorse cardiac myosin inhibitor use in certain cases, greenlight more intensive physical activity, and expand treatment options for young.
Hypertrophic cardiomyopathy (HCM) is a genetic disorder in the heart caused by variants in sarcomeric proteins that disrupt myocardial function, leading to hypercontractility, hypertrophy, and fibrosis.
(MedPage Today) -- As an adjunct to bypass surgery for ischemic cardiomyopathy, a cardiac shockwave therapy aimed at regenerating ischemic myocardium boosted left ventricular ejection fraction (LVEF) and physical function at 1 year in a small sham.
For the past several decades, research on arrhythmogenic right ventricular (RV) cardiomyopathy has focused on describing the clinical features, genetic underpinnings, and natural history of patients with this condition. Crucial to the field were the initial diagnostic criteria proposed in 1994 and later revised in 2010.
Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies.
(MedPage Today) -- Better imaging parameters may exist for risk stratification in nonischemic dilated cardiomyopathy (NIDCM), based on a meta-analysis. The presence and extent of late gadolinium enhancement (LGE) on cardiac MRI was a significant.
Diabetic cardiomyopathy (DCM) is a severe cardiovascular complication of diabetes characterized by myocardial hypertrophy, fibrosis, and impaired cardiac function. Fibroblast growth factor 21 (FGF21) has emerg.
This patient-level meta-analysis of a variety of randomized clinical trials examines the association between mean Kansas City Cardiomyopathy Questionnaire treatment effects and the absolute differences in the proportion of patients experiencing clinically meaningful improvement.
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes. This meta-analysis sought to determine the efficacy of mavacamten and aficamten in hypertrophic cardiomyopathy. years in intervention vs 60.9±10.5
Background Chagas cardiomyopathy (CHCM) is the most important clinical manifestation of Chagas disease. The analysis of cardiac miRNAs may contribute to predicting the progression to CHCM in Chagas indeterminate phase and/or to the differential diagnosis for cardiomyopathy.
Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.
Food and Drug Administration’s ( FDA ) Breakthrough Device Designation for their ECGvision-TTR Technology for early detection of ATTR-Cardiomyopathy. ECGvision-TTR was developed through state-of-the-art deep learning algorithms and offers the unique ability to analyze 12-lead ECG images to detect signatures of ATTR Cardiomyopathy.
Among patients with transthyretin amyloidosis with cardiomyopathy, the risk of death from any cause and recurrent cardiovascular events was lower with vutrisiran treatment than with placebo.
BackgroundHypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder characterized by asymmetric hypertrophy of the ventricles and the ventricular septum, leading to subsequent left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction.
(MedPage Today) -- Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval. Vutrisiran, a transthyretin-directed.
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC: Basic to Translational Science.
microRNAs translocate into subcellular organelles to modify genes involved in diabetic cardiomyopathy. Malonylation, a posttranslational modification of Ago2, reduced the importing of Ago2 into mitochondria in diabetic cardiomyopathy. BACKGROUND:Diabetes is associated with cardiovascular complications.
Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, 24, taking place April 6-8, 2024 in Atlanta, Georgia. 24 , taking place April 6-8, 2024 in Atlanta, Georgia.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden cardiac death in young people and children, with an annual mortality rate of 1%. However, 10% to 20% of these patients have a significantly higher risk of sudden cardiac death.
This cohort study evaluates the association of late gadolinium enhancement with sudden cardiac death or relevant associated events among patients younger than 21 years with hypertrophic cardiomyopathy.
This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.
Hypertrophic cardiomyopathy is the most common genetic cardiac disorder and is defined by the presence of left ventricular (LV) hypertrophy in the absence of a condition capable of producing such a magnitude of hypertrophy. Over the past decade, guidelines on the screening, diagnostic, and management protocols of pediatric primary (i.e.,
I was there and said, "No, I think this is all due to severe chronic cardiomyopathy and cardiac arrest due to primary ventricular fibrillation, not due to ACS." _ Why did I say that? Patient has an ICD, which is primarily placed in patients with cardiomyopathy. The bedside echo showed dilated cardiomyopathy with relatively thin walls.
Dilated cardiomyopathy (DCM) is a common heart muscle disorder of nonischemic etiology associated with heart failure development and the risk of malignant ventricular arrhythmias and sudden cardiac death. Circulation: Genomic and Precision Medicine, Ahead of Print.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content